SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Cempra, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline – CEMP

STEVENSON, Md., Nov. 07, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of purchasers of Cempra, Inc. (Nasdaq:CEMP) (“Cempra” or the “Company”) securities during the period between May 1, 2016 and November 1, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until January 3, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Cempra securities during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Cempra’s lead product candidate solithromycin posed significant safety risks for hepatotoxicity.

According to the complaint, following the November 2, 2016 posting of the briefing documents on solithromycin by the United States Food and Drug Administration reporting that a significant safety signal for hepatotoxicity was observed in the development program and there was concern for the high rate of infusion site-related reactions, the value of Cempra shares declined significantly.  While on November 4, 2016, the U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee narrowly recommended approval of solithromycin saying its effectiveness outweighed the toxicity risks, on November 2, 2016, one analyst reduced the analyst’s estimated peak solithromycin sales by over 75%.

If you have suffered a loss in excess of $100,000 from investment in Cempra securities purchased on or after May 1, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]